about
Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of NeurologyElectrodiagnosis in Persons With Amyotrophic Lateral SclerosisChronic pain in persons with myotonic dystrophy and facioscapulohumeral dystrophy.Impact of biopsychosocial factors on chronic pain in persons with myotonic and facioscapulohumeral muscular dystrophyChronic pain in persons with neuromuscular disease.Cannabis in palliative medicine: improving care and reducing opioid-related morbidity.Pain in youths with neuromuscular diseaseAdaptations to exercise training and contraction-induced muscle injury in animal models of muscular dystrophy.Neuro-inflammation as a therapeutic target in amyotrophic lateral sclerosis.Electrodiagnostic evaluation of hereditary motor and sensory neuropathies.Psychosocial factors and adjustment to pain in individuals with postpolio syndromePsychoactive substances and the political ecology of mental distressMedical marijuana: emerging applications for the management of neurologic disorders.Distal symmetrical polyneuropathy: a definition for clinical research. A report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.Rehabilitation management of peripheral neuropathy.Using electromyography to assess function in humans and animal models of muscular dystrophy.Medical marijuana: politics trumps science at the FDA.Modafinil reduces fatigue in Charcot-Marie-Tooth disease type 1A: a case series.The importance of assessing quality of life in patients with neuromuscular disorders.Iatrogenic axillary neuropathy after intramuscular injection of the deltoid muscle.Chronic pain in neuromuscular disease: pain site and intensity differentially impacts function.Brain death and organ transplantation.Pain in persons with postpolio syndrome: frequency, intensity, and impact.The amyotrophic lateral sclerosis center: a model of multidisciplinary management.Coping with chronic pain among younger, middle-aged, and older adults living with neurological injury and disease.Rehabilitation management of neuromuscular disease: the role of exercise training.New clinical end points in rehabilitation medicine: tools for measuring quality of life.Assessment and management of fatigue in neuromuscular disease.Symptom burden in persons with myotonic and facioscapulohumeral muscular dystrophy.Aging with muscular dystrophy: pathophysiology and clinical management.Hypohomocysteinemia: a potentially treatable cause of peripheral neuropathology?Skeletal muscle edema in muscular dystrophy: clinical and diagnostic implications.Exercise in neuromuscular diseases.Disease burden in neuromuscular disease: the role of chronic pain.Using palliative care in progressive neuromuscular disease to maximize quality of life.ALS Untangled No. 20: the Deanna protocol.Considerations for neuropathic pain conditions in life care planning.The magnetic resonance imaging spectrum of facioscapulohumeral muscular dystrophy.From 32 ounces to zero: a medical geographic study of dispensing a cultivated batch of "plum" cannabis flowers to medical marijuana patients in Washington State.Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials.
P50
Q27001213-E04F172F-4396-476E-822F-A9ACCEC9C9F2Q29013127-48676448-016F-4E87-9F55-72393D49C372Q33689720-54466BCD-32A7-40AD-AFC6-F0CB33C3A9FEQ33752517-C241763E-0FD1-46D9-B54A-50908FADF9D1Q33987789-577D0CEF-9EAA-4498-9D5C-A02611E59B27Q34173898-96D30BC7-7352-4EE6-AC98-7F70B365D72FQ34528306-B0ED3883-5A63-43AB-A119-095C58C9CAF8Q34985410-183A39DA-DDFF-492B-8A18-F97F4CB42EFCQ35045218-FD7E4921-FC9B-480F-939B-3A70437845FCQ35149266-DCB75121-7E5D-4659-B710-FA561BD7A37BQ35169538-2DE668A0-A262-4CB2-B717-F71A25D5BFF8Q35753586-6E95CDC1-4C0C-4D0E-B86A-E2D0826758B2Q35905708-5ED1B4E4-6AF2-480D-81ED-DE796E5478B0Q36004693-8737B135-4DC4-4CAD-B2EA-34E5A20AF03EQ36152887-D7661E13-69B1-4DD2-8DE2-0D1684FF2EC3Q36281142-797C0023-BD77-4FD9-9660-C841D925D990Q36574520-45D2BEDD-6A11-40AA-9293-EF7343EB80ABQ36632760-D429365D-9CCE-44A3-A190-9E9AEA8B33A1Q36702551-1D8A8C66-B3FE-45C5-8964-BC157E50B1B4Q36827724-76A131D0-7542-485D-A0B2-B66239B13103Q36894858-60F50966-7298-439F-9AC2-393280D6FD84Q36951522-1230C630-A8DA-4914-B39F-DF73746B1FA9Q37118259-526A0143-DDB9-47E6-AD52-498C496A5A7DQ37215751-34AB79DA-8677-4418-BB21-427D399E9A8EQ37277515-F4F99F93-410E-4777-B3D0-589A45681D6DQ37591771-77B02859-7D0E-4F31-9C99-67DA95E95B15Q37634844-F041F061-C7B2-403C-B98E-9D99B28CBEA7Q37700000-6EC78BA9-2050-4596-863F-0FEE07E59489Q37710219-1BE3355E-3AE7-496D-B5F8-A3A9BEF2379AQ37759850-2593BCCF-372C-4BFC-AF50-C849BE494BECQ37975313-782DBDAF-9004-4B58-B220-C809015CDBFBQ37975317-530C5516-CA63-43FB-B33F-54160F09E8ADQ38039562-58B9C326-4A87-420A-894B-E58E6EEC9A06Q38039566-A68A4D59-5920-47D6-8CF8-C075506FFB36Q38058628-E75C41FE-838D-46E8-98C7-24F54420494BQ38103571-57A13E43-C45B-499E-B6B4-1C829181BA9AQ38126167-E68C94D6-84D2-4261-BD5C-44B37365BEE5Q39638871-5F6FA5A7-736E-422E-8607-4817D6C99309Q40128346-ED111E87-8FD3-4770-ADC7-177643072B1CQ43075467-B25E0DF5-BFDB-48B9-AFD9-9A18231B1E42
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Gregory Carter
@ast
Gregory Carter
@en
Gregory Carter
@es
Gregory Carter
@nl
Gregory Carter
@sl
type
label
Gregory Carter
@ast
Gregory Carter
@en
Gregory Carter
@es
Gregory Carter
@nl
Gregory Carter
@sl
prefLabel
Gregory Carter
@ast
Gregory Carter
@en
Gregory Carter
@es
Gregory Carter
@nl
Gregory Carter
@sl
P1006
P214
P1006
P106
P21
P214
P31
P496
0000-0001-7617-4750
P734
P735
P7859
viaf-306220183